Tirzepatide linked to rare drug-induced liver injury in a 76-year-old patient
A 76-year-old woman developed biopsy-confirmed drug-induced liver injury after 8 weeks of tirzepatide use, representing one of the few reported cases of this rare side effect.
Quick Facts
What This Study Found
Biopsy-confirmed drug-induced liver injury developed after 8 weeks of tirzepatide use in a 76-year-old woman with concurrent 16-pound weight loss. Mechanism unknown.
Key Numbers
76-year-old woman. 8 weeks of tirzepatide. 16-pound weight loss. Elevated liver enzymes. Biopsy-confirmed DILI.
How They Did This
Single case report with liver biopsy confirmation of DILI.
Why This Research Matters
As tirzepatide is prescribed to millions for diabetes and obesity, even rare side effects must be documented. Liver injury awareness is critical for early detection and intervention.
The Bigger Picture
Post-marketing pharmacovigilance for GLP-1/GIP drugs is essential as use scales rapidly. Rare hepatotoxicity signals require ongoing monitoring and reporting.
What This Study Doesn't Tell Us
Single case; cannot establish incidence or definitive causation. Other potential causes of liver injury may not have been fully excluded. Mechanism unknown.
Questions This Raises
- ?What is the true incidence of tirzepatide-related liver injury?
- ?Does rapid weight loss contribute to liver enzyme elevation independent of drug toxicity?
- ?Are there predisposing factors for GLP-1/GIP drug hepatotoxicity?
Trust & Context
- Key Stat:
- Biopsy-confirmed DILI Rare drug-induced liver injury developed after 8 weeks of tirzepatide use in an elderly patient
- Evidence Grade:
- Single case report with biopsy confirmation—lowest evidence level but important for safety monitoring.
- Study Age:
- Published in 2025; contributes to post-marketing safety surveillance for tirzepatide.
- Original Title:
- Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.
- Published In:
- ACG case reports journal, 12(4), e01661 (2025)
- Authors:
- Phox, Meagan, Thesing, John, Kilgore, W Ransom, Alderson, Joel
- Database ID:
- RPEP-13046
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
Can tirzepatide damage the liver?
Very rarely. This case report is one of only a few documented instances of tirzepatide causing liver injury. A liver biopsy confirmed the damage. While millions take tirzepatide safely, patients should report symptoms like jaundice, dark urine, or upper abdominal pain to their doctor.
Should I get liver tests while on tirzepatide?
There is no routine recommendation for liver monitoring with tirzepatide, as liver injury is very rare. However, if you experience symptoms suggesting liver problems (yellowing skin, unusual fatigue, dark urine), seek medical attention promptly.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13046APA
Phox, Meagan; Thesing, John; Kilgore, W Ransom; Alderson, Joel. (2025). Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.. ACG case reports journal, 12(4), e01661. https://doi.org/10.14309/crj.0000000000001661
MLA
Phox, Meagan, et al. "Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.." ACG case reports journal, 2025. https://doi.org/10.14309/crj.0000000000001661
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide-Induced Liver Injury: A Rare Medication Side Eff..." RPEP-13046. Retrieved from https://rethinkpeptides.com/research/phox-2025-tirzepatideinduced-liver-injury-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.